Jump to content Jump to menu
Why Register?

Shearman FCPA Website: Cases Logo Shearman & Sterling LLP FCPA.Shearman.com: The One-Stop Resource on the Foreign Corrupt Practices Act

SEC v. Novo Nordisk A/S

 
:
Novo Nordisk - Novo Nordisk A/S
:
SEC Civil
:
May 11, 2009
:
SEC v. Novo Nordisk A/S
:
SEC v. Novo Nordisk A/S, No. 1:09-cv-00862 (D. D.C. 2009)
:
Healthcare-Pharmaceutical
:
Iraq
:
2001; 2002; 2003
:
Representatives of the Iraqi State Company for the Importation and Distribution of Drugs and Medical Appliances (Kimadia).
:
In April 1995, the U.N. adopted Security Council Resolution 986, which permitted the government of Iraq to sell oil and to use proceeds from those sales to purchase humanitarian supplies such as food for the Iraqi people ("U.N. Oil-for-Food Program"). In an extensive scheme, the Iraqi government received illicit payments in the form of surcharges from oil purchasers and kickbacks, often termed "after sales service fees," from humanitarian goods suppliers.The kickback payments were masked by inflating the contract price, usually by 10% of the contract value.According to the SEC's complaint, Novo Nordisk paid illegal kickbacks to the former government of Iraq to secure contracts to provide insulin and other medical supplies to Iraq under the U.N. Oil-for-Food Program. Allegedly, Novo Nordisk characterized these kickbacks as "after-sales service fees," but did not provide any bona fide services. Branches of Novo Nordisk in Greece and Jordan handled the Iraqi sales.

Novo Nordisk allegedly inflated the price of contracts by 10% before submitting them to the United Nations for approval, and then made the illegal payments to Kimadia, a state-owned company that was part of the Iraqi Ministry of Health, recording the payments as commissions in its books and records. The value of business to be obtained was 22,000,000 euros (approx. $22 million).

Without admitting or denying the allegations in the SEC's complaint, filed May 11, 2009, Novo consented, also on May 11, 2009, to entry of a final judgment by which it was enjoined from future books and records and internal controls FCPA violations, and ordered to disgorge $4,321,523 in profits, plus $1,683,556 in pre-judgment interest, and ordered to pay a civil penalty of $3,025,066. The SEC considered remedial acts Novo Nordisk promptly undertook and the cooperation it afforded the SEC in its investigation.

In a separate proceeding Novo Nordisk also agreed to pay a $9 million penalty under a deferred prosecution agreement with the Department of Justice.
:
Books and records (Issuer), Internal controls (Issuer)
:
Civil penalty, Disgorgement, Injunction/Cease and desist
:
Disgorgement of $4,321,523 plus pre-judgment interest of $1,683,556, and a civil penalty of $3,025,066.
:
9,030,145
:
0
:
Issuer
:
Foreign
:
Contract Procurement/Retention
:
22,000,000
:
Wire/check
:
Sales Agent/Consultant
:
1,400,000
:
Greece, Jordan
:
Jordan
:
No
:
No